JP2010506147A - 関節リウマチを有する患者のための疾患進行のリスク評価 - Google Patents

関節リウマチを有する患者のための疾患進行のリスク評価 Download PDF

Info

Publication number
JP2010506147A
JP2010506147A JP2009529589A JP2009529589A JP2010506147A JP 2010506147 A JP2010506147 A JP 2010506147A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2010506147 A JP2010506147 A JP 2010506147A
Authority
JP
Japan
Prior art keywords
markers
patients
score
disease progression
crp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506147A5 (https=
Inventor
カール，ヨハン
グルネルト，ファイト
ロリンガー，ウォルフガング
ヴィルト，ノルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010506147A publication Critical patent/JP2010506147A/ja
Publication of JP2010506147A5 publication Critical patent/JP2010506147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009529589A 2006-09-29 2007-09-25 関節リウマチを有する患者のための疾患進行のリスク評価 Pending JP2010506147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020645 2006-09-29
EP06021887 2006-10-19
PCT/EP2007/008313 WO2008037420A1 (en) 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2010506147A true JP2010506147A (ja) 2010-02-25
JP2010506147A5 JP2010506147A5 (https=) 2010-07-15

Family

ID=38859738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529589A Pending JP2010506147A (ja) 2006-09-29 2007-09-25 関節リウマチを有する患者のための疾患進行のリスク評価

Country Status (6)

Country Link
US (1) US8058013B2 (https=)
EP (1) EP2074428B1 (https=)
JP (1) JP2010506147A (https=)
CA (1) CA2663730A1 (https=)
ES (1) ES2545688T3 (https=)
WO (1) WO2008037420A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012103238A (ja) * 2010-10-14 2012-05-31 Nagasaki Univ 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
US10718765B2 (en) 2014-04-02 2020-07-21 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US10983120B2 (en) 2015-09-29 2021-04-20 Crescendo Bioscience Methods for assessing response to inflammatory disease therapy withdrawal
US11493512B2 (en) 2014-06-10 2022-11-08 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity
US11656227B2 (en) 2015-09-29 2023-05-23 Crescendo Bioscience Biomarkers and methods for assessing psoriatic arthritis disease activity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
US20130246097A1 (en) * 2010-03-17 2013-09-19 Howard M. Kenney Medical Information Systems and Medical Data Processing Methods
JP5786020B2 (ja) * 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
WO2012012183A2 (en) * 2010-06-30 2012-01-26 New York University Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments
EP2635966A4 (en) * 2010-11-06 2014-06-04 Crescendo Bioscience BIOMARKERS FOR PREDICTING PROGRESSIVE GLAND DAMAGE
WO2014151238A1 (en) * 2013-03-15 2014-09-25 Exagen Diagnostics, Inc. Methods for treating and diagnosing systemic lupus erythematosus
JP2015061592A (ja) * 2013-08-21 2015-04-02 コニカミノルタ株式会社 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体
GB201603571D0 (en) * 2016-03-01 2016-04-13 Univ Warwick Markers for skeletal disorders
US20220390466A1 (en) * 2019-10-30 2022-12-08 Cd Diagnostics, Inc. Biomarkers of early osteoarthritis
CN114089632B (zh) * 2021-11-15 2023-08-18 陕西师范大学 基于模糊逻辑的风湿免疫疾病特征识别方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085859A1 (en) * 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105893D0 (en) * 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU3746295A (en) * 1994-10-17 1996-05-06 Osteometer Biotech As Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
FR2752842B1 (fr) 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
CZ20001963A3 (cs) 1997-11-28 2002-04-17 Innogenetics N. V. Peptidy obsahující citrulin rozeznaný sérem revmatické artritidy jako prostředky pro diagnózu a léčbu
FR2773157B1 (fr) 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
NZ504683A (en) * 1998-01-09 2002-06-28 Pfizer Amide derivatives and pharmaceutical compositions thereof and their use as matrix metalloprotease inhibitors
DE1240180T1 (de) 1999-12-21 2003-08-14 Innogenetics N.V., Gent Peptide zur diagnose und behandlung rheumatischer arthritis
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085859A1 (en) * 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
US9200324B2 (en) 2009-10-15 2015-12-01 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US11300575B2 (en) 2009-10-15 2022-04-12 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring inflammatory disease activity
JP2012103238A (ja) * 2010-10-14 2012-05-31 Nagasaki Univ 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
US10718765B2 (en) 2014-04-02 2020-07-21 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US11493512B2 (en) 2014-06-10 2022-11-08 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity
US10983120B2 (en) 2015-09-29 2021-04-20 Crescendo Bioscience Methods for assessing response to inflammatory disease therapy withdrawal
US11656227B2 (en) 2015-09-29 2023-05-23 Crescendo Bioscience Biomarkers and methods for assessing psoriatic arthritis disease activity
US12385912B2 (en) 2015-09-29 2025-08-12 Laboratory Corporation Of America Holdings Methods of treatment of arthritic disorders

Also Published As

Publication number Publication date
EP2074428A1 (en) 2009-07-01
US20090270272A1 (en) 2009-10-29
WO2008037420A1 (en) 2008-04-03
ES2545688T3 (es) 2015-09-15
EP2074428B1 (en) 2015-07-01
CA2663730A1 (en) 2008-04-03
US8058013B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
US8058013B2 (en) Assessing risk of disease progression in rheumatoid arthritis patients
Visser Early diagnosis of rheumatoid arthritis
Yamanaka et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis
Hurnakova et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis
JP4495168B2 (ja) 抗ｃｃｐおよびインターロイキン６の測定による慢性関節リウマチの評価方法
US8062907B2 (en) Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A
CN101283278A (zh) 在类风湿性关节炎的诊断中的抗ccp和抗核抗体
Fex et al. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet.
CN101523218B (zh) 评估类风湿性关节炎患者疾病进展的风险
JP4610605B2 (ja) リウマチ因子およびインターロイキン６の測定による慢性関節リウマチの評価方法
Yasin et al. Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis
CN104105967B (zh) 生腱蛋白c及其在类风湿关节炎的用途
HK1136628B (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
HK1136628A (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
El Kosaier et al. Serum amyloid a level and musculoskeletal ultrasound in assessment of disease activity in rheumatoid arthritis patients
WO2012098256A1 (en) Anti-cd146 auto-antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120508